New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016. Review uri icon

Overview

abstract

  • This report is a summary of 'New Cancer Immunotherapy Agents in Development' program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical and pre-clinical immune-based agents and combinations, before participating in an extended panel discussion with multidisciplinary leaders, including members of the FDA, leading academic institutions and industrial drug developers, to consider topics relevant to the future of cancer immunotherapy.

authors

  • Adusumilli, Prasad
  • Cha, Edward
  • Cornfeld, Mark
  • Davis, Thomas
  • Diab, Adi
  • Dubensky, Thomas W
  • Evans, Elizabeth
  • Grogan, Jane L
  • Irving, Bryan A
  • Leidner, Rom S
  • Olwill, Shane A
  • Soon-Shiong, Patrick
  • Triebel, Frederic
  • Tuck, David
  • Bot, Adrian
  • Dansey, Roger D
  • Drake, Charles G
  • Freeman, Gordon J
  • Ibrahim, Ramy
  • Patel, Salil
  • Chen, Daniel S

publication date

  • June 20, 2017

Research

keywords

  • Cancer Vaccines
  • Immunotherapy
  • Neoplasms
  • Tumor Microenvironment

Identity

PubMed Central ID

  • PMC5477277

Scopus Document Identifier

  • 85021065315

Digital Object Identifier (DOI)

  • 10.1186/s40425-017-0253-2

PubMed ID

  • 28649381

Additional Document Info

volume

  • 5